The present invention is used for diagnosis, including early diagnosis, of malignant growths, for assessment as of the extent of malignant infection, for determining of the required volume for surgical intervention, for finalizing diagnoses under clinical and dispensary conditions, for control during the process of treatment of malignant tumors, and for detection of post-operative relapses. The contrasting composition according to the present invention is characterized in that, in addition to the contrasting composition, namely, fluorescein, or salts thereof, it comprises sugar.
A fuel-lean mixture burns in rows of flame ports each located between a pair of rows of flame ports burning a fuel-rich mixture. The fuel-rich flames support and stabilize the fuel-lean flames to stabilize combustion and to avoid flame liftoff and noise. The fuel-lean flames reduce the temperature of the overall flame, and thereby reduce the production of No.sub.x compounds produced by the burner. Stepwise and proportional burner control techniques are disclosed.
Disclosed are methods of therapy applicable to pathologies that involve loss of integrity of tissue and organ membranes that lead to abnormal permeation of proteinic and other agents and their elimination or penetration of other anatomical functions. Such deficiencies are associated directly or indirectly, for example, with inflammatory diseases, with diabetes and others. The therapeutic method involves administering to the membrane in need of treatment a therapeutic amount of an oligosaccharide, preferably a cyclic oligosaccharide, having up to about 10 sugar units per molecule and having at least 1.4 anionic substituents per sugar unit. The anionic substituents are preferably the residues of strong acids.
A method for cancer cell detection including the steps of (a) staining an analyzed sample with at least first and second dyes, the dyes being selected such that the first dye better adheres to normal cells whereas the second dye better adheres to cancer cells; (b) spectrally imaging the sample through an optical device being optically connected to an imaging spectrometer thereby obtaining a spectrum of each pixel of the sample; (c) based on the spectra, evaluating concentrations of the first and second dyes for each of the pixels; and (d) based on the concentrations detecting the presence of cancer cells in the sample.
